Evaluation of the CYP3A and CYP2B6 Drug‐Drug Interaction Potential of Lemborexant

Lemborexant is approved for treating insomnia and is under investigation for treating irregular sleep‐wake rhythm disorder. Based on in vitro drug‐drug interaction (DDI) characteristics, phase 1, open‐label DDI studies were conducted to evaluate lemborexant's cytochrome P450 3A (CYP3A) and CYP2...

Descripción completa

Detalles Bibliográficos
Autores principales: Landry, Ishani, Aluri, Jagadeesh, Nakai, Kenya, Hall, Nancy, Miyajima, Yukiko, Ueno, Takashi, Dayal, Satish, Filippov, Gleb, Lalovic, Bojan, Moline, Margaret, Reyderman, Larisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248323/
https://www.ncbi.nlm.nih.gov/pubmed/33455055
http://dx.doi.org/10.1002/cpdd.915

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248323/
https://www.ncbi.nlm.nih.gov/pubmed/33455055
http://dx.doi.org/10.1002/cpdd.915

Ejemplares similares